Gamma sensory stimulation safe, effective in those with Alzheimer’s disease

SEATTLE — Self-administered home use of gamma sensory stimulation reduced brain atrophy safely in people with Alzheimer’s disease, a presenter said at the 2022 American Academy of Neurology annual meeting.
Mihaly Hajos, PharmD, PhD, chief scientific officer at Cognito Therapeutics and adjunct professor at Yale University, and colleagues evaluated the safety, tolerability and efficacy of 40-Hz gamma sensory stimulation in patients with AD.
In a phase 1/2 randomized, controlled, single-blind multicenter clinical trial using the GammaSense Stimulation device (Cognito Therapeutics), 74

SEATTLE — Self-administered home use of gamma sensory stimulation reduced brain atrophy safely in people with Alzheimer’s disease, a presenter said at the 2022 American Academy of Neurology annual meeting.
Mihaly Hajos, PharmD, PhD, chief scientific officer at Cognito Therapeutics and adjunct professor at Yale University, and colleagues evaluated the safety, tolerability and efficacy of 40-Hz gamma sensory stimulation in patients with AD.
In a phase 1/2 randomized, controlled, single-blind multicenter clinical trial using the GammaSense Stimulation device (Cognito Therapeutics), 74